Business Context and Reporting Period
This Form 8-K filing by Conduit Pharmaceuticals Inc. (CDT) reports material definitive agreements and unregistered sales of equity securities. The report covers events occurring on October 28, 2024, and October 29, 2024, with the filing date of November 1, 2024. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Agreements
- Bridge Loan (A.G.P.): Entered into a Bridge Loan Agreement for an advance not to exceed $600,000. The promissory note bears interest at 4.21% per annum and matures on December 31, 2024.
- Warrant Issuance (A.G.P.): Issued warrants to purchase up to 2,862,596 shares of common stock at an exercise price of $0.1048 per share as partial consideration for the bridge loan.
- Nirland Note: Issued a new promissory note for $600,000 on October 28, 2024. The note bears interest at 12% per annum (increasing to 18% upon default), matures on October 31, 2025, and includes a 1% arrangement fee.
- Existing Nirland Debt: Previously held a Senior Secured Promissory Note of $2,650,000 (inclusive of a $500,000 original issuance discount).
- At-the-Market Offering: The company intends to undertake an offering of up to approximately $3.5 million, with initial proceeds designated to repay the A.G.P. Bridge Note.
Material Changes and Amendments
- Debt Amendment (Nirland): On October 31, 2024, the company amended its existing debt agreements with Nirland Limited. Key changes include:
- Added a provision allowing Nirland to convert the existing note into common stock at its discretion.
- Removed Nirland's mandatory prepayment right.
- Removed Nirland's right of first refusal to participate in future equity or debt offerings.
- Fee Suspension (A.G.P.): Amended a prior fee letter agreement to suspend the requirement to pay A.G.P. 25% of net proceeds from certain transactions until the Bridge Note is repaid in full.
Outlook, Risks, and Contingencies
- Stockholder Approval: The issuance of common stock upon exercise of the A.G.P. warrants is subject to stockholder approval under Nasdaq rules. The company must convene a stockholder meeting within 90 days of warrant issuance if required.
- Liquidity Strategy: The company plans to use proceeds from its upcoming at-the-market offering to repay the short-term A.G.P. Bridge Note due in December 2024.
- Default Risk: The Nirland Note includes a penalty interest rate of 18% per annum in the event of a default.
- Unregistered Securities: The warrants and the convertible features of the amended Nirland note were issued under Section 4(a)(2) exemptions and are not registered under the Securities Act of 1933.
Investor Verification Checklist
- Verify the status of the stockholder meeting required to approve the issuance of shares underlying the A.G.P. warrants.
- Confirm the timeline and execution of the at-the-market offering intended to repay the $600,000 A.G.P. Bridge Note due December 31, 2024.
- Review the specific conversion rate terms for the amended Nirland Existing Note to assess potential dilution.
- Monitor the company's cash position to ensure it can service the 12% interest on the new Nirland Note and the 4.21% interest on the Bridge Note.